Bevacizumab Plus mFOLFOX6 vs mFOLFOX6 Alone as First-Line Treatment for RAS-Mutant Unresectable Colorectal Liver-Limited Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial
J. Clin. Oncol 2020 Aug 04;[EPub Ahead of Print], W Tang, L Ren, Q Ye, Y Wei, G He, Q Lin, X Wang, M Wang, F Liang, Y Cui, T Liu, J XuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.